Abivax is preparing a regulatory submission in the U.S. in the second half of 2026, provided an ongoing maintenance trial ...

Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Today we discuss why comparing U.S. vaccine policy to Europe’s is a red herring, why the revolving door at the FDA between ...

Using patented purification methods and a community-first growth strategy, the Root Brands is redefining what it means to ...

Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences ...

Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...

What China is accomplishing in R&D “has implications for everyone playing in the R&D or innovation world,” McKinsey’s Fangning Zhang says.

As of Monday, December 08, Legend Biotech Corporation’s LEGN share price has dipped by 8.82%, which has investors questioning if this is right time to buy.

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...

The Department of Health and Human Services recently canceled $500 million in funding for vaccine research that it had previously pledged to scientists.

Breakthrough Properties is raising a $1.5B fund to buy discounted lab assets as the market struggles with high vacancy and ...